Table 4.
Antiproliferative effect of somatostatin analogues in patients with progressive disease.
| SSA | Dosage | N | CR | PR | SD | PD | References |
|---|---|---|---|---|---|---|---|
| Lanreotide | 3000 mg/day | 22 | 0 | 1 | 7 | 14 | [97] |
| Lanreotide | 30 mg/2 weeks | 35 | 0 | 1 | 20 | 14 | [90] |
| Octreotide | 600 and 1500 mg/day | 52 | 0 | 0 | 19 | 33 | [74] |
| Octreotide | 1500 and 3000 mg/day | 58 | 0 | 2 | 27 | 29 | [26] |
| Lanreotide | 15000 mg/day | 24 | 1 | 1 | 11 | 11 | [97] |
| Octreotide | 600 mg/day | 10 | 0 | 0 | 5 | 5 | [73] |
| Octreotide | median dose of 250 μg three times daily | 34 | 0 | 1 | 17 | 0 | [75] |
| Octreotide LAR 30/ Lanreotide SR |
60 mg/28 days | 31 | 0 | 0 | 14 | 4 | [76] |
| Total | 256 | 1 | 6 | 115 | 105 | ||
| Percentage | (%) | 0.3 | 2 | 45 | 41 |
SSA, somatostatina analogues; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.